Insulin detemir in combination with oral antidiabetic drugs improves glycemic control in persons with type 2 diabetes in Near East countrie

LAUR Repository

Show simple item record

dc.contributor.author Echtay, Akram
dc.contributor.author Andari, Emile
dc.contributor.author Atallah, Paola
dc.contributor.author Moufarrege, Roland
dc.contributor.author Nemr, Rita
dc.date.accessioned 2019-05-29T11:35:12Z
dc.date.available 2019-05-29T11:35:12Z
dc.date.copyright 2017 en_US
dc.date.issued 2019-05-29
dc.identifier.issn 1945-0826 en_US
dc.identifier.uri http://hdl.handle.net/10725/10696
dc.description.abstract Objective To evaluate the effectiveness and safety of insulin detemir treatment as add-on therapy in a real-world setting of Lebanese insulin naïve persons, with type 2 diabetes poorly controlled on oral antidiabetic drugs (OADs). Methods Our study was a prospective, observational study representing the Lebanese arm of the multinational prospective and observational study involving 2,155 persons across Near East countries, Lebanon, Pakistan, Israel and Jordan. Effectiveness endpoints were changes in HbA1c, fasting and post-prandial glucose (FPG, PPG) after 24 weeks of treatment with insulin detemir in eligible persons. Safety endpoints were number of hypoglycemic events, incidence of adverse drug reactions (ADRs), serious ADRs, adverse events, and body weight change between baseline and end of treatment. Results 868 persons were included (mean age: 59.5 ± 10.4 years, men: 55.3%). Glycemic control improved with significant reduction in mean HbA1c from 9.7 ± 1.6% to 7.2 ± 1% (P<.0001). The percentage of persons who achieved the target of HbA1c<7% increased from .7% at baseline to 39% at week 24. Mean FPG decreased significantly from 213.7 ± 60.1 mg/dL to 120.3 ± 25.7 mg/dL (P<.001), and mean PPG from 271 ± 65.3 mg/dL to 158.1 ± 36.4 mg/dL (P<.0001). The rate of major hypoglycemic episodes decreased from .1498 at baseline to .0448 at week 24. Three adverse events but no ADR or serious ADR were reported. Body weight decreased from 80.4±13.2 Kg to 79.9±12.5 Kg (P<.0001). Conclusions Initiating insulin detemir in a clinical health care setting among Lebanese with type 2 diabetes mellitus on OADs improves glycemic control with no increase in hypoglycemia, adverse events or weight compared with baseline. en_US
dc.language.iso en en_US
dc.title Insulin detemir in combination with oral antidiabetic drugs improves glycemic control in persons with type 2 diabetes in Near East countrie en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201004815 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Ethnicity & Disease en_US
dc.journal.volume 27 en_US
dc.journal.issue 1 en_US
dc.article.pages 45-54 en_US
dc.keywords Glycemic Control en_US
dc.keywords Insulin Detemir en_US
dc.keywords Lebanese Population en_US
dc.keywords Oral Antidiabetic Drugs en_US
dc.keywords Type 2 Diabetes Mellitus en_US
dc.identifier.doi http://dx.doi.org/10.18865/ed.27.1.45 en_US
dc.identifier.ctation Echtay, A., Andari, E., Atallah, P., Moufarrege, R., & Nemr, R. (2017). Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup. Ethnicity & disease, 27(1), 45. en_US
dc.author.email rita.nemr@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245608/ en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account